{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:39:34Z","timestamp":1758587974309,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006556","name":"Centre Hospitalier Universitaire de Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.therap.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:14:59Z","timestamp":1559042099000},"page":"651-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pourquoi, comment et o\u00f9 dose-t-on les antihypertenseurs en 2019\u00a0?"],"prefix":"10.1016","volume":"74","author":[{"given":"B\u00e9atrice","family":"Bouhanick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Fonquernie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"India","family":"Bedue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Schavgoulidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Prise en charge de l\u2019hypertension art\u00e9rielle de l\u2019adulte. Fiche m\u00e9mo, rapport d\u2019\u00e9laboration","author":"Gourbail","key":"10.1016\/j.therap.2019.05.002_bib0240"},{"issue":"12","key":"10.1016\/j.therap.2019.05.002_bib0245","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018\u00a0update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"33","key":"10.1016\/j.therap.2019.05.002_bib0250","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018\u00a0ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.therap.2019.05.002_bib0255","first-page":"170","article-title":"L\u2019hypertension art\u00e9rielle en France\u00a0: pr\u00e9valence, traitement et contr\u00f4le en 2015\u00a0et \u00e9volution depuis 2006","author":"Perrine","year":"2018","journal-title":"Bull Epidemiol Hebd"},{"issue":"1","key":"10.1016\/j.therap.2019.05.002_bib0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension","volume":"16","author":"Weber","year":"2014","journal-title":"J Clin Hypertens"},{"issue":"13","key":"10.1016\/j.therap.2019.05.002_bib0265","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2016.01.044","article-title":"Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke","volume":"67","author":"Herttua","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.therap.2019.05.002_bib0270","first-page":"814","article-title":"The implications of therapeutic complexity on adherence to cardiovascular medications","volume":"171","author":"Choudhry","year":"2011","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.therap.2019.05.002_bib0275","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.therap.2019.05.002_bib0280","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/HJH.0000000000001299","article-title":"Drug adherence in hypertension: from methodological issues to cardiovascular outcomes","volume":"35","author":"Hamdidouche","year":"2017","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.therap.2019.05.002_bib0285","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.113.00687","article-title":"Measuring, analyzing, and managing drug adherence in resistant hypertension","volume":"62","author":"Burnier","year":"2013","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.therap.2019.05.002_bib0290","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2337\/dc06-0255","volume":"29","author":"Azizi","year":"2006","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.therap.2019.05.002_bib0295","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","article-title":"High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis","volume":"100","author":"Tomaszewski","year":"2014","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.therap.2019.05.002_bib0300","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/HJH.0000000000001402","article-title":"Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients","volume":"35","author":"Hamdidouche","year":"2017","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0305","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.vascn.2008.03.002","article-title":"Comparison of different pharmacodynamic models for PK\u2013PD modeling of verapamil in renovascular hypertension","volume":"57","author":"Bertera","year":"2008","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"10.1016\/j.therap.2019.05.002_bib0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00045391-199408000-00003","article-title":"Concentration\/effect analysis of antihypertensive drugs","volume":"1","author":"Harder","year":"1994","journal-title":"Am J Ther"},{"issue":"4","key":"10.1016\/j.therap.2019.05.002_bib0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s002280100323","article-title":"Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine","volume":"57","author":"Breithaupt-Gr\u00f6gler","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.05.002_bib0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.yrtph.2016.01.003","article-title":"Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects","volume":"76","author":"Kiriyama","year":"2016","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2019.05.002_bib0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003088-200241020-00005","article-title":"Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers","volume":"41","author":"Csajka","year":"2002","journal-title":"Clin Pharmacokinet"},{"year":"2016","series-title":"Fiche m\u00e9mo HAS. Prise en charge de l\u2019hypertension art\u00e9rielle de l\u2019adulte","author":"Haute Autorit\u00e9 de sant\u00e9","key":"10.1016\/j.therap.2019.05.002_bib0330"},{"year":"2019","series-title":"Logiciel WebPlotDigitizer","key":"10.1016\/j.therap.2019.05.002_bib0335"},{"key":"10.1016\/j.therap.2019.05.002_bib0340","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie. Suivi th\u00e9rapeutique pharmacologique et personnalisation des traitements. https:\/\/www.pharmacol-fr.org\/catalogue-des-analyses [Consult\u00e9 le 21\u00a0mai 2019]."},{"year":"2019","series-title":"Open Medic\u00a0: base compl\u00e8te sur les d\u00e9penses de m\u00e9dicaments interr\u00e9gimes","key":"10.1016\/j.therap.2019.05.002_bib0345"},{"key":"10.1016\/j.therap.2019.05.002_bib0350","article-title":"Le codage des actes biologiques\u00a0-\u00a0NABM","author":"Ameli","year":"2017","journal-title":"Main"},{"issue":"7","key":"10.1016\/j.therap.2019.05.002_bib0355","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1472-8206.1991.tb00749.x","article-title":"A comparative pharmacokinetic and pharmacodynamic study of conventional and sustained-release preparations of acebutolol in healthy volunteers","volume":"5","author":"Fleurot","year":"1991","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.therap.2019.05.002_bib0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2125.1983.tb02138.x","article-title":"A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics","volume":"16","author":"Ishizaki","year":"1983","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.therap.2019.05.002_bib0365","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00870987","article-title":"Interaction of bisoprolol with cimetidine and rifampicin","volume":"31","author":"Kirch","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2019.05.002_bib0370","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00562615","article-title":"A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metoprolol","volume":"17","author":"Kendall","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.therap.2019.05.002_bib0375","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1023\/A:1018960626925","article-title":"Steady-state bioavailability and day-to-day variability of a multiple-unit (CR\/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing","volume":"10","author":"Sandberg","year":"1993","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.therap.2019.05.002_bib0380","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0091270010370846","article-title":"Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies","volume":"51","author":"Lindamood","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0385","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01065394","article-title":"Pharmacokinetics of propranolol in normal healthy volunteers","volume":"5","author":"Gomeni","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"10.1016\/j.therap.2019.05.002_bib0390","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/j.1552-4604.1987.tb03036.x","article-title":"Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol","volume":"27","author":"Garg","year":"1987","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.therap.2019.05.002_bib0395","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/j.1552-4604.1987.tb05584.x","article-title":"Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation","volume":"27","author":"Marino","year":"1987","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.therap.2019.05.002_bib0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","article-title":"The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14\u00a0repeated oral doses given once daily","volume":"22","author":"Faulkner","year":"1986","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0405","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00192556","article-title":"A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets","volume":"46","author":"Leeuwenkamp","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0410","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/bdd.2510100309","article-title":"Multiple dose comparison of a whole 240mg verapamil sustained-release tablet with two half tablets","volume":"10","author":"Moreland","year":"1989","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0415","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00005344-199209000-00024","article-title":"Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects","volume":"20","author":"Louis","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0420","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2013.02.015","article-title":"Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2\u00a0inhibitor, and verapamil, ramipril, or digoxin in healthy volunteer","volume":"35","author":"Macha","year":"2013","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.therap.2019.05.002_bib0425","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects","volume":"38","author":"Marino","year":"1998","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.therap.2019.05.002_bib0430","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s002280050317","article-title":"Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects","volume":"52","author":"M\u00fcller","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2019.05.002_bib0435","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cpt1969103401","article-title":"The metabolism of amiloride hydrochloride in man","volume":"10","author":"Weiss","year":"1969","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2019.05.002_bib0440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cpt1974152178","article-title":"Pharmacokinetics of orally administered furosemide","volume":"15","author":"Michael","year":"1974","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.therap.2019.05.002_bib0445","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF00607430","article-title":"Pharmacokinetics of hydrochlorothiazide in man","volume":"12","author":"Beermann","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u00a0Pt 2","key":"10.1016\/j.therap.2019.05.002_bib0450","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0002-8703(83)90119-9","article-title":"Vukovich RA.0\u00a0Pharmacokinetics and clinical pharmacology of indapamide","volume":"106","author":"Caruso","year":"1983","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.therap.2019.05.002_bib0455","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cpt1976192158","article-title":"Spironolactone. I. Disposition and metabolism","volume":"19","author":"Karim","year":"1976","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.therap.2019.05.002_bib0460","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2146\/ajhp060033","article-title":"Medication and nutrient administration considerations after bariatric surgery","volume":"63","author":"Miller","year":"2006","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10.1016\/j.therap.2019.05.002_bib0465","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.116.022922","article-title":"Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial","volume":"134","author":"Azizi","year":"2016","journal-title":"Circulation"},{"year":"2017","series-title":"La strat\u00e9gie nationale de sant\u00e9 pour les maladies hypertensives\u00a0: propositions de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019hypertension art\u00e9rielle","author":"Soci\u00e9t\u00e9 fran\u00e7aise d\u2019hypertension art\u00e9rielle","key":"10.1016\/j.therap.2019.05.002_bib0470"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595719300940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:29Z","timestamp":1758567209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595719300940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0040595719300940"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2019.05.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pourquoi, comment et o\u00f9 dose-t-on les antihypertenseurs en 2019\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}